INBS vs. NEPH, SPAI, ECOR, POCI, QTI, MODD, PYPD, NMTC, COCH, and TMDIF
Should you be buying Intelligent Bio Solutions stock or one of its competitors? The main competitors of Intelligent Bio Solutions include Nephros (NEPH), Safe Pro Group (SPAI), electroCore (ECOR), Precision Optics (POCI), QT Imaging (QTI), Modular Medical (MODD), PolyPid (PYPD), NeuroOne Medical Technologies (NMTC), Envoy Medical (COCH), and Titan Medical (TMDIF). These companies are all part of the "medical equipment" industry.
Intelligent Bio Solutions vs. Its Competitors
Intelligent Bio Solutions (NASDAQ:INBS) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.
33.0% of Intelligent Bio Solutions shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 1.5% of Intelligent Bio Solutions shares are owned by company insiders. Comparatively, 6.7% of Nephros shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Intelligent Bio Solutions has a beta of 4.6, meaning that its share price is 360% more volatile than the S&P 500. Comparatively, Nephros has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500.
In the previous week, Nephros had 1 more articles in the media than Intelligent Bio Solutions. MarketBeat recorded 1 mentions for Nephros and 0 mentions for Intelligent Bio Solutions. Intelligent Bio Solutions' average media sentiment score of 0.00 equaled Nephros'average media sentiment score.
Nephros has a consensus target price of $5.00, suggesting a potential upside of 22.55%. Given Nephros' stronger consensus rating and higher possible upside, analysts clearly believe Nephros is more favorable than Intelligent Bio Solutions.
Nephros has a net margin of 5.16% compared to Intelligent Bio Solutions' net margin of -319.85%. Nephros' return on equity of 9.43% beat Intelligent Bio Solutions' return on equity.
Nephros has higher revenue and earnings than Intelligent Bio Solutions.
Summary
Nephros beats Intelligent Bio Solutions on 11 of the 13 factors compared between the two stocks.
Get Intelligent Bio Solutions News Delivered to You Automatically
Sign up to receive the latest news and ratings for INBS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding INBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Intelligent Bio Solutions Competitors List
Related Companies and Tools
This page (NASDAQ:INBS) was last updated on 7/8/2025 by MarketBeat.com Staff
Free INBS Stock Alerts